Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 1.11B 991M 918M 835M 1.57B 105B 1.59B 11.01B 4.33B 55.1B 4.17B 4.08B 176B P/E 2026 *
12x
P/E 2027 * 9.9x
Enterprise Value 1.42B 1.26B 1.17B 1.06B 1.99B 134B 2.03B 14.02B 5.51B 70.14B 5.31B 5.2B 224B EV / Sales 2026 *
1.89x
EV / Sales 2027 * 1.65x
Free-Float
47.23%
Yield 2026 *
-
Yield 2027 * -
1 day+1.04%
1 week-2.32%
Current month+1.28%
1 month+10.67%
3 months+32.39%
6 months+14.25%
Current year-2.39%
1 week 25.52
Extreme 25.515
27.1
1 month 23.45
Extreme 23.45
27.8
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
29.52
3 years 16.64
Extreme 16.645
65.92
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 28/02/1996
Chief Operating Officer 76 28/02/1996
Director of Finance/CFO 58 31/03/2014
Director TitleAgeSince
Chairman 76 28/02/1996
Director/Board Member 79 28/02/1996
Director/Board Member 58 03/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Sell

Chief Financial Officer

-4,139 0.0097%
16/09/26 Exercice

Chief Technology Officer

30,000 0.0705%
02/09/26 Sell

Chief Technology Officer

-3,187 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%-2.32%+9.92%-41.69% 1.11B
-1.33%+4.88%+54.50%+109.94% 1,106B
-0.69%-3.77%+31.35%+66.62% 612B
-0.96%+0.55%+23.13%+94.26% 500B
+1.45%+7.34%+37.39%+61.59% 367B
-1.59%-1.25%+69.39%+43.02% 354B
+0.89%+5.16%+20.47%+47.95% 286B
+0.38%+4.71%-0.86%+19.42% 256B
-1.75%+1.76%+42.21%+51.44% 230B
-2.00%+1.75%+24.64%+95.14% 190B
Average +0.46%+1.63%+31.21%+54.77% 390.13B
Weighted average by Cap. +0.77%+2.30%+38.28%+75.81%

Financials

2026 *2027 *
Net sales 748M 667M 617M 561M 1.05B 70.89B 1.07B 7.41B 2.91B 37.05B 2.81B 2.75B 118B 784M 699M 648M 589M 1.11B 74.37B 1.12B 7.77B 3.05B 38.87B 2.94B 2.88B 124B
Net income 99.32M 88.53M 82.01M 74.57M 140M 9.42B 142M 984M 387M 4.92B 373M 365M 15.73B 115M 103M 95.31M 86.66M 163M 10.94B 165M 1.14B 450M 5.72B 433M 424M 18.28B
Net Debt 303M 270M 251M 228M 427M 28.77B 435M 3.01B 1.18B 15.04B 1.14B 1.11B 48.06B 184M 164M 152M 138M 259M 17.46B 264M 1.82B 717M 9.12B 691M 676M 29.17B
Projected Income Statement - Annual - Amphastar Pharmaceuticals, Inc.
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
19/10/26 US$26.14 +1.04% 299,510
16/10/26 US$25.87 -2.08% 352,084
15/10/26 US$26.42 +1.30% 352,436
14/10/26 US$26.08 +0.12% 364,655
13/10/26 US$26.05 -2.65% 326,547
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Amphastar Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
26.14USD
Average target price
22.50USD
Spread / Average Target
-13.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amphastar Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. AMPH Stock